Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 719

1.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

PMID:
15068497
[PubMed - indexed for MEDLINE]
2.

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.

Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE.

Menopause. 2004 Jul-Aug;11(4):405-15.

PMID:
15243278
[PubMed - indexed for MEDLINE]
3.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
[PubMed - indexed for MEDLINE]
4.

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH.

Osteoporos Int. 2008 Jul;19(7):1055-65. doi: 10.1007/s00198-007-0557-z. Epub 2008 Feb 19.

PMID:
18283386
[PubMed - indexed for MEDLINE]
5.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11. Epub 2005 Jul 18.

PMID:
16234962
[PubMed - indexed for MEDLINE]
6.

Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.

Sanad Z, Ellakwa H, Desouky B.

Climacteric. 2011 Jun;14(3):369-77. doi: 10.3109/13697137.2010.537408. Epub 2011 Jan 23.

PMID:
21254911
[PubMed - indexed for MEDLINE]
7.

[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):269-73. Chinese.

PMID:
15059505
[PubMed - indexed for MEDLINE]
8.

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.

J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853.

PMID:
23281041
[PubMed - indexed for MEDLINE]
9.

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.

Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.

J Intern Med. 2004 Apr;255(4):503-11.

PMID:
15049885
[PubMed - indexed for MEDLINE]
10.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
[PubMed - indexed for MEDLINE]
11.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
[PubMed - indexed for MEDLINE]
12.

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.

Osteoporos Int. 1999;10(4):330-6. Erratum in: Osteoporos Int 1999;10(5):433.

PMID:
10692984
[PubMed - indexed for MEDLINE]
13.

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

J Bone Miner Res. 1998 Sep;13(9):1431-8.

PMID:
9738515
[PubMed - indexed for MEDLINE]
14.

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.

Bone. 2010 Apr;46(4):935-9. doi: 10.1016/j.bone.2009.12.032. Epub 2010 Jan 6.

PMID:
20060081
[PubMed - indexed for MEDLINE]
15.

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

Keel C, Kraenzlin ME, Kraenzlin CA, Müller B, Meier C.

J Bone Miner Metab. 2010;28(1):68-76. doi: 10.1007/s00774-009-0101-7. Epub 2009 Jun 17.

PMID:
19633810
[PubMed - indexed for MEDLINE]
16.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78.

PMID:
8833208
[PubMed - indexed for MEDLINE]
17.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
[PubMed - indexed for MEDLINE]
18.

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.

Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.

PMID:
19877063
[PubMed - indexed for MEDLINE]
Free Article
19.

Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.

Clin Ther. 2004 Feb;26(2):245-56.

PMID:
15038947
[PubMed - indexed for MEDLINE]
20.

Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.

Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA.

J Bone Miner Res. 2006 Feb;21(2):283-91. Epub 2005 Oct 31.

PMID:
16418784
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk